Dataset opportunity
Duchefa Biochemie — Regulatory Records Dataset Opportunity
Moderate regulatory records dataset held by Duchefa Biochemie, usable for Regulatory RAG and Compliance Copilots.
Score
70
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
Acquire
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
Global Regulatory Information Management system market = $2.2 billion in 2024, CAGR 10.9%.
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
- ✨Signal
Maintains a complete raw material traceability system and ISO 9001/GMP standards
source ↗
Profile
Dataset profile
Type
Regulatory Records Dataset
Modality
Text
Sector
healthcare
Volume
Moderate
Freshness
Periodic
Rarity
High (proprietary)
Accessibility
Partial
Legal
Owned by the company — clean to license
Buyer persona
RegTech & compliance-AI vendors
Duchefa Biochemie holds a specialized Regulatory Records Dataset in Text modality, containing detailed business records, industrial data, and regulatory filings. This includes proprietary formulations, quality control logs from LIMS, and historical submission documents, making it an exceptionally rich source for training a Regulatory RAG system to navigate complex compliance and biochemical inquiries.
The value of this data is underscored by the Global Regulatory Information Management market, which was valued at $2.2 billion in 2024 and is projected to grow at a CAGR of 10.9%. While access requires navigating NDAs for proprietary formulations, the rarity and high-value nature of this industrial_data offer a significant competitive advantage for an AI buyer, justifying the negotiated access. ⚠ Diligence (valuable data, access to negotiate): Proprietary formulations for custom media are often under non-disclosure agreements with clients; Data is likely stored in laboratory information management systems (LIMS) and quality control logs · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence collectively proves Duchefa Biochemie holds a deep, proprietary dataset of internal regulatory records governing the production of specialized biochemicals. These documents detail adherence to critical standards like GMP and ISO 9001, including complete raw material traceability. For RegTech and compliance-AI vendors, this dataset is a rare asset for building and fine-tuning Regulatory RAG systems, a crucial capability in the rapidly growing $2.2 billion global regulatory information management market.
See dimension details ↓- Dataset Specificity78
dominant 'regulatory', sector healthcare, 2 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity70
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
periodic
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value74
fit for Regulatory RAG
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand85
AI buyer demand is high, driven by the significant growth in the Global Regulatory Information Management market, which is expanding at a 10.9% CAGR.
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility50
restricted/unknown
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility44
low difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 evidence types, 3 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License92
ownership=company_owned, licensing=clean
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation39
1 data-appetite signals (1 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit92
✓ good target — Duchefa Biochemie is a producer and wholesaler of biochemicals for plant tissue culture, which generates regulatory and production data as a by-product and does not appear to sell it. Issues: The exact number of employees is not publicly available, so SME status is an estimation based on the company's description and operational scope.
- Deep Qualification90
⚠ needs review — The target is a data holder with coherent regulatory data, but ownership is mixed and licensing is restricted for custom formulations. Crucially, its data domain (plant science) does not match the specified niche (medical devices). [licensing restricted; entity does not hold the niche's characteristic data: The target's data relates to plant biotechnology and phytopathology regulations, not 'Medical Device Regulatory Compliance' as defined by the niche.]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Industrial data
This evidence confirms the existence of detailed product specifications and manufacturing data for over 300 custom media formulations, providing essential operational context for the associated regulatory filings.
business_records
This is direct proof of internal quality control documentation, demonstrating a complete raw material traceability system and adherence to global GMP and ISO 9001 standards.
Regulatory records
This evidence points to a specialized corpus of regulatory text focused on niche life sciences applications, including phytopathology and seed health testing, valuable for training models on specific industry verticals.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Duchefa Biochemie Regulatory Records — a Moderate regulatory records dataset (Text modality) in the healthcare domain. Primary AI use-case: Regulatory RAG. Market signal: Global Regulatory Information Management system market = $2.2 billion in 2024, CAGR 10.9% (source: Global Market Insights, Inc.). Investment score 70.0/100 (confidence 0.49). Recommended action: Acquire.
From the marketplace
Explore live data opportunities
Georgebakershipping — Regulatory Records Dataset Opportunity
View opportunity →healthcareStarseq — Medical Imaging Dataset Opportunity
View opportunity →healthcareIcentia — Medical Imaging Dataset Opportunity
View opportunity →Data Academy
Learn before you deal
- 5 Mistakes That Drive Buyers Away3 min read
- Why Buy External Data?3 min read
- Buying Data Without Mistakes3 min read